Your JM Support Community
Cure JM helps patients and their families navigate life with juvenile myositis.
Cure JM is the global leader in juvenile myositis (JM) research. We are paving the way to better treatments for JM while improving the lives of families affected by the disease.
About
Juvenile Myositis
Juvenile myositis involves a run-away immune response where the body’s immune system attacks its own cells and tissues. With proper treatment and care, children can go on to live their best lives.
Resources
ProDerm Study Reports Milestone in Treating Adult Myositis
Recently, the Progress in Dermatomyositis (ProDERM) study published in the New England Journal of Medicine reported a milestone in managing adult myositis. With the trial’s
Abatacept Trial Concludes With Favorable Results In JM Treatment
A clinical trial treating patients with juvenile myositis with the drug abatacept resulted in lower disease activity and clinically significant responses in most patients. The
Cure JM Research Consortium Receives Prestigious Chan Zuckerberg Grant
The Chan Zuckerberg Initiative has awarded Cure JM and a consortium of Cure JM-funded researchers a coveted $2 million rare disease research grant to identify
Finding a Cure and Better Treatments for Juvenile Myositis
Cure JM is accelerating juvenile myositis research at an unprecedented pace. We are pursuing promising new treatments, funding clinical trials, and improving care for patients.
Research
New Treatments
Trials
Care Network
Current Events
The Chan Zuckerberg Initiative has awarded Cure JM and a consortium of Cure JM-funded researchers a coveted $2 million rare disease research grant to identify new biomarkers in JM and improve precise, personalized care through the identification of cell-to-cell interactions that drive inflammation in juvenile myositis.
The Cure JM Family Conference is back! Join families from around the country to learn about the latest treatment and research advances to share in our hope and progress.
Save the Date: Thursday, June 29–Sunday, July 2, 2023
ProDerm Study Reports a Milestone in Managing Adult Myositis
Recently, the Progress in Dermatomyositis ProDERM study published in the New England Journal of Medicine reported a milestone in managing adult myositis. With the trial’s favorable results, adult myositis patients have new hope with the approval of Octagam® 10%.
A clinical trial treating patients with juvenile myositis with the drug abatacept resulted in lower disease activity and clinically significant responses in most patients.
“Cure JM has provided us so much support and connected us to so many families that were experiencing or had experienced the exact same thing. That sense of community helped us get through the ups and downs.”
Join Cure JM
Membership is free and we’ll connect you with a network of support, encouragement, and resources.
